financing

News

Anthropic sets out its biopharma ambitions in IPO doc

Anthropic says it is working with nine of the top 10 pharma groups in its IPO prospectus, which also reiterates AI's "existential risks to humanity."

News

UK biotech financing shoots up, setting up "a record year"

UK biotech shrugged off a difficult economic environment with a 44% increase in venture capital investment in the third quarter to £270m, says BIA.

News

Cancer biotech Nouscom adds €120m, and other financings

A €120m Series D for Swiss biotech Nouscom will support trials of a Lynch syndrome vaccine, with Soufflé, Estuary, and Microbiotica also raising cash.

News

RNAi biotech City hauls in $200m in upsized IPO

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

News

Could OMass become the UK's 'big biotech' company?

UK-based OMass Therapeutics' ambition to join the 'big biotech' ranks has been bolstered by an impressive $310m third-round financing.

News

Bambusa, Aspen, and Tang added to IPO pipeline

2026's sizeable haul of IPOs shows no signs of letting up, with three more biotechs – Bambusa, Aspen, and blank cheque firm Tang – joining the queue.

Anthropic sets out its biopharma ambitions in IPO doc

UK biotech financing shoots up, setting up "a record year"

Cancer biotech Nouscom adds €120m, and other financings

RNAi biotech City hauls in $200m in upsized IPO

Could OMass become the UK's 'big biotech' company?

Bambusa, Aspen, and Tang added to IPO pipeline

Astellas pays $285m for Audax cancer drug, and other deals

Discover a new era of healthcare panel engagement: Grounded ...

financing

Editor's Picks